title: Long-term maintenance treatment with omeprazole in children with healed erosive oesophagitis: a prospective study.
abstract: BACKGROUND
  Short-term studies show that PPIs heal erosive esophagitis in children. There are no prospective studies that examine long-term maintenance therapy of erosive esophagitis in children with and without underlying GERD-predisposing disorders.
  
  
  OBJECTIVE
  To determine prospectively the dose of omeprazole needed to maintain remission of erosive oesophagitis and reflux symptoms in children.
  
  
  METHODS
  Patients aged 1-16 years with healed erosive reflux oesophagitis after omeprazole treatment (0.7-3.5 mg/kg/day) entered a 21-month maintenance phase where they initially received half the dose of omeprazole required to heal. Endoscopy was performed after 3, 12 and 21 months. The omeprazole dose was increased if erosive oesophagitis or reflux symptoms recurred.
  
  
  RESULTS
  A total of 46 patients entered the study and 32 completed it. Of these, 17 (53%) remained on the maintenance dose, 12 (38%) returned to their healing dose and 3 (9%) ended the study on a dose higher than their healing dose. Three-quarters of the completers (24/32) had no erosive oesophagitis relapse. Four patients (13%) had relapse of only erosive oesophagitis, 4 (13%) had relapse of erosive oesophagitis and symptoms, and 10 (31%) had only symptomatic relapse. Of the 46 patients, 48% had GERD-predisposing disorders (neurological impairment or oesophageal atresia). Overall, 62.5% (5/8) of patients who had an erosive oesophagitis relapse had a GERD-predisposing disorder versus 33.3% (8/24) of those who did not.
  
  
  CONCLUSIONS
  Remission of erosive oesophagitis is maintained with omeprazole treatment for at least 21 months in most children aged 1-16 years, and the drug is well tolerated. To maintain remission, some 60% of patients require more than half the dose required for healing. In children with GERD-predisposing conditions, GERD is often chronic and relapsing, and requires long-term management.
authors.affiliation: Division of Gastroenterology, British Columbia Children's Hospital/University of British Columbia, Vancouver, Canada. hassale@sutterhealth.org
authors.forename: E
authors.initials: E
authors.lastname: Hassall
authors.forename: R
authors.initials: R
authors.lastname: Shepherd
authors.forename: S
authors.initials: S
authors.lastname: Koletzko
authors.forename: M
authors.initials: M
authors.lastname: Radke
authors.forename: C
authors.initials: C
authors.lastname: Henderson
authors.forename: P
authors.initials: P
authors.lastname: Lundborg
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D004941:Esophagitis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007223:Infant; D008134:Long-Term Care; D008297:Male; D009853:Omeprazole / Q000008:administration & dosage*; D011446:Prospective Studies; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D009853:Omeprazole